Literature DB >> 32211093

Interaction between CXCR4 and EGFR and downstream PI3K/AKT pathway in lung adenocarcinoma A549 cells and transplanted tumor in nude mice.

Juan Wu1, Ying Liu1, Yaling Ma1, Rui Wang1, Xiaokun Ji1, Yan Zhang1, Yun Du1.   

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality all over the world, particularly in China. Metastasis is the main factor resulting in the poor prognosis of patients with NSCLC. CXCR4 and EGFR have been widely studied due to their critical role in tumor metastasis, but it remains more elusive then the relationship between CXCR4 and EGFR. Studies have demonstrated that many tumors have been found the existence of the "cross-talk" between EGFR and CXCR4 signaling pathways. In this context, we explored the relationship between EGFR and CXCR4 signaling pathways in lung cancer invasion and metastasis by both in vitro and in vivo experiments. IJCEP
Copyright © 2020.

Entities:  

Keywords:  Lung adenocarcinoma; PI3K/AKT signaling pathway; chemokine receptor 4; epidermal growth factor receptor; invasion

Year:  2020        PMID: 32211093      PMCID: PMC7061788     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  20 in total

Review 1.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

2.  Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha.

Authors:  Roderick J Phillips; Javier Mestas; Mehrnaz Gharaee-Kermani; Marie D Burdick; Antonio Sica; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  J Biol Chem       Date:  2005-03-31       Impact factor: 5.157

3.  Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding.

Authors:  Lisa Héron-Milhavet; Celine Franckhauser; Vanessa Rana; Cyril Berthenet; Daniel Fisher; Brian A Hemmings; Anne Fernandez; Ned J C Lamb
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

Review 4.  Oncogenic PI3K and its role in cancer.

Authors:  Yardena Samuels; Kajsa Ericson
Journal:  Curr Opin Oncol       Date:  2006-01       Impact factor: 3.645

5.  Signaling mechanisms coupled to CXCL12/CXCR4-mediated cellular proliferation are PTEN-dependent.

Authors:  Lesa A Begley; Sathish Kasina; Rajal B Shah; Jill A Macoska
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

6.  Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity.

Authors:  Yanhong Wu; Zhenling Deng; Yishu Tang; Shuren Zhang; Yu-Qian Zhang
Journal:  BMC Cancer       Date:  2015-08-27       Impact factor: 4.430

7.  Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma.

Authors:  Huanwen Wu; Liang Zhu; Hui Zhang; Xiaohua Shi; Li Zhang; Wenze Wang; Huadan Xue; Zhiyong Liang
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

8.  CXCL12/CXCR4 Axis Activation Mediates Prostate Myofibroblast Phenoconversion through Non-Canonical EGFR/MEK/ERK Signaling.

Authors:  José A Rodríguez-Nieves; Susan C Patalano; Diego Almanza; Mehrnaz Gharaee-Kermani; Jill A Macoska
Journal:  PLoS One       Date:  2016-07-19       Impact factor: 3.240

Review 9.  Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.

Authors:  Stefan Langhammer; Joachim Scheerer
Journal:  Oncotarget       Date:  2017-06-27

10.  Crosstalk Between MAPK/ERK and PI3K/AKT Signal Pathways During Brain Ischemia/Reperfusion.

Authors:  Jing Zhou; Ting Du; Baoman Li; Yan Rong; Alexei Verkhratsky; Liang Peng
Journal:  ASN Neuro       Date:  2015-10-06       Impact factor: 4.146

View more
  1 in total

1.  The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.

Authors:  Liping Qiu; Yuanyuan Xu; Hui Xu; Biyun Yu
Journal:  BMC Cancer       Date:  2022-06-21       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.